Assessing the Growth Trajectory of Three Under-$2B Companies in 2026

The setup for small-cap growth is clear. The Russell 2000 has been the standout performer, hitting all-time highs and surging 7.8% year to date through early January, far outpacing the S&P 500's 1.5% advance. This rally is being driven by a potent mix of macro tailwinds: expectations for Federal Reserve rate cuts later this year and strong domestic economic data. Small caps, which tend to be more domestically focused, are particularly sensitive to these shifts, making them a prime beneficiary of the current cycle.

This momentum has also sparked a significant rotation within the market. Investors are moving capital away from larger, more established firms. Bank of America data shows clients were net sellers of large stocks in 2025, dumping $45.9 billion, while simultaneously adding to small-cap positions. This rotation provides a powerful tailwind for the growth thesis, as capital flows toward companies with higher growth potential and greater scalability.

Yet, the path forward is not without friction. The technical picture suggests the rally may be getting stretched. The Russell 2000's relative strength index sits at 71, a level that signals the index is overbought and potentially due for a pullback. Barclays traders echo this caution, noting that while the iShares Russell 2000 ETF has recently outpaced broader indices, the opportunity set is less compelling and they would prefer to take profits. This creates a nuanced environment: the macro tailwinds and rotation are real, but the momentum itself is becoming a less compelling reason to buy.

For the growth investor, this sets the stage. The investment opportunity now hinges less on chasing the broad momentum and more on identifying the specific companies within the small-cap universe that can truly capitalize on these conditions. The focus must shift to market penetration and scalability-the core drivers of high-growth returns. The macro backdrop provides the runway, but the real alpha will come from selecting firms with the operational models and addressable markets to dominate their niches.

Deep Dive: Kraken Robotics - Penetrating the UUV Market

Kraken Robotics is targeting a high-growth niche with its revolutionary SeaPower batteries, and recent developments point to a clear path for scaling within the unmanned underwater vehicle (UUV) segment. The company's primary growth catalyst is a $35 million in battery sales to three unnamed customers, a contract that validates its technology for commercial deployment. This isn't just a one-off order; it signals increasing momentum and provides a tangible revenue stream to fund further expansion.

The core of Kraken's competitive edge lies in the technical leap its batteries provide. SeaPower offers 200% greater energy density and 46% less weight per kWh compared to traditional solutions. This isn't a marginal improvement. It directly translates to extended mission durations, deeper operational ranges, and the ability to carry more sophisticated payloads-all critical for defense, commercial seabed mapping, and marine research applications. For UUV operators, this means more data collected per sortie and reduced need for costly surface support, making Kraken's power systems a compelling upgrade.

Scalability is the next critical phase, and Kraken is actively building the capacity to meet rising demand. The company is bringing manufacturing capacity online in North America in Q1 2026, complementing its existing European operations. This geographic diversification of production is a strategic move to secure supply chains and reduce lead times as the UUV market expands. With manufacturing coming online, Kraken is positioning itself to supply power systems across the entire UUV spectrum, from extra-large to small vehicles, as it looks to integrate on several new platforms throughout 2026.

For the growth investor, Kraken presents a classic small-cap story with a clear technological moat and a scalable manufacturing ramp. The $35 million contract provides near-term validation, while the technical specs define a superior product. The upcoming North American production capacity is the linchpin for capturing a larger share of the expanding UUV market. The company's focus on subsea intelligence through integrated sensors and power solutions suggests a holistic approach to dominating its niche.

Deep Dive: Enovix - Scaling 3D Silicon Anode Batteries for AI

Enovix is a company at the inflection point, transitioning from a promising battery technology to a scalable commercial supplier. With a market capitalization of $1.63 billion, it sits squarely in the small-cap growth category, offering a significant runway for expansion. The company's core mission is to bring its proprietary 3D silicon anode battery technology to market, and its recent manufacturing milestone marks a critical step toward that goal.

The pivotal development is the successful completion of Site Acceptance Testing (SAT) for its High Volume Manufacturing (HVM) line in Malaysia. This is not a minor operational check; it is a formal validation that the production line can consistently manufacture the company's advanced batteries at scale. For a firm focused on high-energy-density solutions, this achievement is the linchpin for capturing market share. It de-risks the commercialization path, moving Enovix from a prototype developer to a potential volume supplier.

This timing is strategic, aligning with a looming global energy crisis that could bottleneck the very industries Enovix serves. Experts warn that the explosive growth of artificial intelligence is pushing power grids to their limits, with figures like Elon Musk stating "AI will run out of electricity by next year." The narrative is clear: AI is the most electricity-hungry technology ever invented, and without a breakthrough in energy density or efficiency, its growth could be constrained. Enovix's 3D silicon anode batteries, which promise higher energy density than conventional lithium-ion, are positioned as a potential solution to this problem. They could extend the operational life of AI-powered devices and data center equipment, effectively stretching the available power supply.

For the growth investor, Enovix represents a dual-play opportunity. The first is the direct commercialization of its manufacturing capability, which could unlock new revenue streams in consumer electronics, industrial tools, and potentially electric vehicles. The second, and more speculative, is its alignment with the AI energy demand narrative. If the warnings about an impending power crunch prove accurate, the demand for high-efficiency batteries like Enovix's could surge, accelerating the company's growth trajectory. The successful SAT is the foundational step that makes both scenarios plausible.

Deep Dive: Aehr Test Systems - Capitalizing on AI Hardware Demand

Aehr Test Systems is a clear beneficiary of the AI hardware build-out, with its growth trajectory now defined by a major customer ramp and a scalable manufacturing model. The company's core business-providing test and burn-in equipment for semiconductors-has found a powerful niche in the production of AI processors, where reliability and yield are paramount.

The immediate catalyst is a significant order from a world-leading hyperscaler. Aehr recently received follow-on volume production orders for eight Sonoma ultra-high-power systems to be used for the burn-in of the customer's AI processors. This represents a more than doubling of the number of production systems with this key client, a move that validates Aehr's technology for high-volume manufacturing. The customer, which is developing its own AI chips and expanding capacity, has already begun discussing next-generation processors with Aehr, signaling a long-term partnership. For a growth investor, this is the gold standard: a major customer not only placing a large order but also committing to future generations of its products.

This visibility is backed by a solid financial position. As of the end of its fiscal second quarter, Aehr's backlog stood at $11.8 million, with effective backlog-including recent bookings-reaching $18.3 million. The eight Sonoma systems from the hyperscaler order are scheduled to ship from Aehr's high-volume production facility in Fremont over the next six months, providing a clear revenue pipeline for the coming quarters. This order flow offers a tangible counterpoint to the company's recent quarterly revenue softness, which was noted in its latest financial report.

The market is clearly pricing in this growth story. Aehr's market capitalization has surged, increasing by 63% in one year to reach approximately $859 million as of late January. This dramatic re-rating reflects investor confidence in the company's ability to capture a growing share of the semiconductor test market, which is being reshaped by the AI chip boom. The TAM is vast, with the AI chip market projected to grow from over $60 billion in 2023 to more than $600 billion by 2032. Aehr's focus on providing a low-cost, integrated solution for packaged-part burn-in positions it to scale alongside its customers' capacity expansions.

The bottom line is that Aehr has moved from a niche supplier to a critical enabler in the AI hardware supply chain. Its growth is now tied to the success of its hyperscaler customer's AI processor roadmap, providing a clear and scalable path forward. For the growth investor, the company offers a leveraged play on the AI infrastructure build-out, with a validated customer relationship and a manufacturing ramp that can meet rising demand.

Valuation and Risk Assessment from a Growth Perspective

All three companies are valued under $2 billion, a fact that underscores their substantial growth runway. Aehr Test Systems trades at a market capitalization of $859 million, while Enovix is valued at $1.63 billion. For a growth investor, this size is the starting point. It means these firms have the operational flexibility and market share potential to deliver multi-year double-digit growth before reaching the scale of larger peers. Their recent stock performance reflects this potential, with Aehr's market cap surging 63% in one year as the market priced in its AI hardware story.

Yet, the path to that growth is fraught with execution and market risks. The most immediate challenge is scaling manufacturing. For Enovix, the successful SAT of its High Volume Manufacturing line is a critical milestone, but the real test is maintaining that pace as demand rises. For Kraken Robotics, bringing North American production online in Q1 2026 is the linchpin for capturing the expanding UUV market. Any delays or cost overruns in these scale-up efforts could stall revenue growth and erode investor confidence.

Customer concentration is another key vulnerability, particularly for Aehr. Its growth is now tied to a single, world-leading hyperscaler for AI processors. While the recent order for eight Sonoma systems represents a more than doubling of production systems with this client, it also concentrates a significant portion of near-term revenue. The company's visibility is strong, with an effective backlog of $18.3 million, but the risk of a customer shift or a slowdown in their chip ramp remains a material concern.

Beyond company-specific issues, these firms operate in cyclical industries. Aehr serves the semiconductor sector, which is inherently volatile. Kraken's UUV market is driven by defense and commercial seabed mapping budgets, which can fluctuate with government spending and economic conditions. This cyclicality introduces an element of unpredictability that can pressure margins and capital expenditure plans during downturns.

The overarching risk, however, is a shift in the broader market environment. The small-cap rally that has fueled these valuations is showing signs of strain. The Russell 2000's relative strength index sits at 71, a level that signals the index is overbought and potentially due for a pullback. Barclays traders have noted that the opportunity set is less compelling, suggesting the momentum itself may be a headwind. If this rally fades, the valuation premium for high-growth, pre-profitability names like these three companies could compress, making it harder to fund their expansion plans. For the growth investor, the thesis remains intact, but the margin of safety is thinner.